Global & USA Cancer Immunotherapy Market Analysis & Forecast to 2022

  • ID: 4415804
  • Report
  • Region: Global, United States
  • 370 pages
  • Kelly Scientific Publications
1 of 7

FEATURED COMPANIES

  • Ablynx NV
  • Biogen Idec Inc
  • Eli Lilly and Co.
  • Immunocore Ltd.
  • Merck & Co., Inc
  • Regen Biopharma Inc
  • MORE

Global & USA Cancer Immunotherapy Market Analysis & Forecast to 2022: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors

Within the cancer therapeutics space, which today is worth over $100 billion globally, immunotherapeutic drugs have gained worldwide acceptance. This is because they are targeted therapeutics that have high specificity for cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022. This report describes the evolution of such a huge market in 20 chapters supported by over 180 tables and figures in 340 pages.

Highlights of the Report

  • An overview of cancer immunotherapy that includes: monoclonal antibodies, ADC’s, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
  • Focus on current trends in cancer immunotherapies that include: anti-PD-1 and anti-PDL1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.
  • Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
  • Descriptions of more than 23 cancer immunotherapeutics approved and used as targeted drugs
  • Insight into the various immunotherapeutics available for specific cancer types.
  • Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
  • Overall global cancer therapeutics market, leading market players and the best selling cancer drugs.
  • Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs.
  • Profiles, marketed products and products in the pipeline of 79 companies that are located globally
  • Summary table to identify the category of immunotherapy drug offered by the 79 companies.
  • Specific chapter on the CAR-T industry detailing manufacturing, regulations and pricing

Key Questions Answered in this Report

  • What is the global market for cancer immunotherapeutics by product class such as MAbs, vaccines and non-specific immunotherapies, through 2022?
  • What is the global market for cancer immunotherapeutics by geography, through 2022?
  • What is the global market for cancer immunotherapeutics by indication, through 2022?
  • What is the global market for MAbs by type such as naked MAbs and ADCs, through 2022?
  • What are the market values for Herceptin, Avastin, Erbitux, Yervoy, Mabthera, Adectris, and Keytruda?
  • What is the global market for cancer vaccines?
  • What is the global market for cytokines in cancer immunotherapy?
  • The projected market values for Nivolumab, Tecentriq, DCVax-L, Imfinzi?
  • What  immunotherapies were approved between 1986 and 2017?
  • What monoclonal antibodies (MAbs) were approved by the FDA to treat different types of cancers?
  • What are naked MAbs and how many of them have been approved by the  FDA?
  • What are antibody-drug conjugates (ADCs) and how many of them are available in the market?
  • What are the common cytotoxic “wareheads” used in ADCs?
  • What are the important clinical assets in ADCs?
  • How many bispecific MAbs are in late-stage development?
  • What are the common side effects of MAbs in cancer immunotherapy?
  • What are cancer vaccines and how many of them have been licensed to be marketed?
  • How many cytokines have been approved for being used in cancer  immunotherapy?
  • What are the major checkpoint inhibitors in clinical development?
  • What is the current status of anti-PD-1 drugs, dentritic cell therapies, T-cell therapies and cancer vaccines?
  • What are the most valuable R&D projects in cancer immunotherapy and what would be their approximate sales revenues in 2022?
  • Number of melanoma drugs approved between 1998 and 2017?
  • Number of lung cancer drugs approved between 1998 and 2017?
  • Number of brain cancer drugs approved between 1998 and 2017?
  • What is CAR T Therapy?
  • What are the main challenges associated with CAR T therapy?
  • What is the status of CAR T therapeutic approval?
  • What are the current regulations for immunotherapies in USA, Europe & Japan?
  • What are the main manufacturing steps in CAR T therapy?
  • What challenges lie ahead for CAR T production?
READ MORE
Note: Product cover images may vary from those shown
2 of 7

FEATURED COMPANIES

  • Ablynx NV
  • Biogen Idec Inc
  • Eli Lilly and Co.
  • Immunocore Ltd.
  • Merck & Co., Inc
  • Regen Biopharma Inc
  • MORE

1.0    Executive Summary                                   
1.1    Objectives of Report                                   
1.2    Key Questions Answered in this Report                           
1.3    Data Sources and Methodology                               

2.0    Cancer Immunotherapy: An Overview                     
2.1    Human Immune System                                  
2.1.1    Components of Human Immune System                          
2.2    Types of Cancer Immunotherapy                          
2.3    Monoclonal Antibodies (Mabs) to Treat Cancer                  
2.3.1    Most Frequently Targeted Antigens by MAbs                      
2.4    Types of Monoclonal Antibodies (MAbs)                          
2.4.1    Naked MAbs                                      
2.4.2    Conjugated Monoclonal Antibodies                          
2.4.2.1    Components of an Antibody Drug Conjugate (ADC)                  
2.4.2.2    Mechanism of Action of Antibody Drug Conjugate (ADC)                  
2.4.2.3    The Cytotoxic Wareheads used in ADCs                          
2.4.2.4    Successful Cytotoxin Wareheads                              
2.4.2.5    Developmental Timeline of ADCs                          
2.4.2.6    Target Antigens for ADCs in Preclinical and Clinical Development                                    
2.4.2.7    Important Clinical Assets in ADCs                          
2.4.3    Bispecific Monoclonal Antibodies                              
2.4.3.1    Technology Platforms for the Production of Bispecific MAbs              
2.4.4    Safety and Side Effects of MAbs in Cancer Immunotherapy              
2.5    Cancer Vaccines                                      
2.5.1    Cancer Vaccines in Development                              
2.6    Non-Specific Cancer Immunotherapies and Adjuvants                  
2.6.1    Cytokines                                      
2.6.2    Interferon (IFN)                                      
2.7    New Frontiers in Cancer Immunotherapy Research                  
2.7.1    Drugs for Targeting Immune Checkpoints                      
2.7.1.1    Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)                  
2.7.1.2    Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)              
2.7.1.3    Major Checkpoint Inhibitors in Clinical Development                  
2.7.2    Chimeric Antigen Receptor (CAR) T Cell Therapy                      
2.7.3    Tumor-Infiltrating Lymphocytes (TILs) and Interleukin-2 (IL-2)          
2.8    Cancer Immunotherapy: Timeline of Progress                      

3.0    Current Status of Cancer Immunotherapy: An Overview               
3.1    Programmed Death (PD-1) Inhibitors                           
3.1.1    Important Events and Advantages for Nivolumab in Melanoma Indication           
3.1.2    Important Events and Advantages for Nivolumab in Non-Small Cell Lung Cancer       
3.1.3    Important Events and Advantages for Nivolumab in Renal Cell Cancer           
3.1.4    Nivolumab Studies for Melanoma                           
3.1.5    Nivolumab Studies for Non-Small Cell Lung Cancer (NSCLC)               
3.1.6    Nivolumab Studies for Renal Cell Cancer (RCC)                       
3.2    Keytruda (Pembrolizumab, MK-3475)                               
3.2.1    Important Events and Advantages for Keytruda in Melanoma               
3.2.2    Important Events and Advantages for Keytruda in NSCLC                   
3.2.3    Important Events for Keytruda in RCC                           
3.3    Tecentriq from Roche                                   
3.3.1    Important Events for Tecentriq in Melanoma                       
3.3.2    Important Events and Advantages for Tecentriq in NSCLC                   
3.3.3    Important Event for Tecentriq in RCC                           
3.3.4    Tecentriq Studies in NSCLC                               
3.3.5    Tecentriq Studies in RCC                                   
3.3.6    Tecentriq Study in RCC                                   
3.4    Pidilizumab from CureTech                               
3.5    An Overview of Anti-PD-1 Clinical Development                       
3.5.1    Other Checkpoint Inhibitors in Development                       
3.6    Studies with Yervoy (Ipilimumab)                           
3.7    Studies with Tremelimumab                               
3.8    KAHR-102                                       
3.9    TIM3 Antibody                                       
3.10    BMS-989016                                       
3.11    ImmuTune IMP701 and ImmuFact IMP321                       
3.12    Dendritic Cell Therapies                                   
3.12.1    Provenge (Sipuleucel-T)                                   
3.12.2    AGS-003 from Argos Therapeutics                           
3.12.3    DCP-001 from DCPrime                                   
3.12.4    DC-Vax from Northwest Biotherapeutics                           
3.13    Chimeric Antigen Receptor T-Cells (CAR-T) Therapies                   
3.13.1    CLT109                                           
3.13.2    Chimeric Antigen Receptors (CAR) Program by Juno                   
3.13.3    Chimeric Antigen Receptor (CAR) T-Cell Program by Bluebird Bio               
3.13.4    UCART19 from Cellectis                                   
3.13.5    Chimeric Immune Receptor (CIR) T-Cells from Abramson Cancer Center           
3.13.6    CD19 eACT CAR-T Therapy from Kite Pharma                       
3.13.7    Autologous CAR-T Program for Breast Cancer from Adaptimmune       
3.14    Cancer Vaccines                                       
3.14.1    HyperAcute                                       
3.14.2    MAGE-A3 Antigen-Specific Cancer Immunotherapeutic                   
3.14.3    ADXS-HPV                                       
3.14.4    IDO Inhibitors                                       
3.14.5    Indoximod and NLG-919 (INCY)                               
3.14.6    INCB24360 (INCY)                                   
3.14.7    deCellVax (BMSN)                                   
3.15    Miscellaneous Immunotherapies                               
3.15.1    Contego (Lion Biotechnologies)                               
3.15.2    TG4010 (Transgene)                                   
3.16    Most Valuable R&D Projects in Cancer Immunotherapy                   
3.16.1    Nivolumab (Opdivo)                                   
3.16.2    Keytruda                                       
3.16.3    Tecentriq                                       
3.16.4    Palbociclib                                       
3.16.5    DCVax-L                                       
3.16.6    Imfinzi                                       

4.0    Challenges in Cancer Medicine Research: An Overview               
4.1    Years of Failures and Emerging Successes in Melanoma Medicine Research       
4.1.1    Future Outlook for Melanoma Drugs                           
4.2    A New Era for Lung Cancer Medicines                           
4.2.1    Progresses Made in Lung Cancer Medicine Research                   
4.2.2    Successes and Failures in Lung Cancer Medicine Development               
4.2.3    Future Outlook for Lung Cancer Medicines                       
4.3    Ray of Hope for Brain Cancer Patients                           
4.3.1    Progress made for Brain Cancer Treatment in Recent Years               
4.3.2    Successes and Failures in Brain Cancer Drug Development               

5.0    Cancer Immunotherapeutic Products: An Overview               
5.1    I-Labelled Tositumomab (Bexxar)                           
5.2    Y-Labelled Ibritumomab (Zevalin)                           
5.3    Alemtuzumab (Campath)                               
5.4    Adotrastuzumab Emtansine (Kadcyla)                           
5.5    Bacillus Calmette-Guerin (BCG)                               
5.6    Bevacizumab (Avastin)                                   
5.7    Brentuximab Vedotin (Adcetris)                               
5.8    Cetuximab (Erbitux)                                   
5.9    Cervarix                                           
5.10    Denileukin Diftitox (Ontak)                               
5.11    Gardasil                                           
5.12    Gemtuzumab (Mylotarg)                                   
5.13    Hepatitis B Vaccine                                   
5.14    Interferon Alfa (IFN-alfa)                               
5.15    Interleukin-2 (IL-2)                                   
5.16    Ipilimumab (Yervoy)                                   
5.17    Ofatumumab (Arzerra)                                   
5.18    Panitumumab (Vectibix)                                   
5.19    Pembrolizumab (Keytruda)                               
5.20    Rituximab (Mabthera)                                   
5.21    Sargramostim (Leukine)                                   
5.22    Sipuleucel-T (Provenge)                                   
5.23    Trastuzumab (Herceptin)                               

6.0    Available Immunotherapies for Cancer by Disease Type: An Overview       
6.1    Melanoma Skin Cancer and Immunotherapy                       
6.1.1    Ipilimumab (Yervoy) for Advanced Melanoma                       
6.1.2    PD-1 Inhibitors (Keytruda and Opdivo) for Advanced Melanoma               
6.1.3    Cytokines for Advanced Melanoma                           
6.1.4    Interferon Alfa as Adjuvant Therapy for Melanoma                   
6.1.5    Bacille Calmette-Guerin (BCG) Vaccine for Melanoma                   
6.1.6    Imiquimod (zyclara) Cream for Melanoma                       
6.2    Breast Cancer and Immunotherapy                           
6.2.1    Promising Therapeutic Vaccine Product Candidates for Breast Cancer           
6.2.2    Promising Checkpoint Inhibiting Product Candidates for Breast Cancer           
6.2.3    Promising Adoptive T Cell Therapy Product Candidates for Breast Cancer           
6.2.4    Promising Antibody Product Candidates for Breast Cancer               
6.3    Immunotherapy for Prostate Cancer                           
6.3.1    Therapeutic Vaccines for Prostate Cancer                       
6.3.2    Checkpoint Inhibitors for Prostate Cancer                       
6.3.3    Adoptive Cell Therapy for Prostate Cancer                       
6.4    Immunotherapy for Lung Cancer                           
6.4.1    Monoclonal Antibodies for Lung Cancer                           
6.4.1.1    Promising MAb Product Candidates for Lung Cancer                   
6.4.1.2    Checkpoint Inhibitors for Lung Cancer                           
6.4.1.3    Therapeutic Vaccines for Lung Cancer                           
6.4.1.4    Promising Adoptive T Cell Transfer Product Candidates for Lung Cancer           
6.5    Immunotherapy for Colorectal Cancer                           
6.5.1    Promising Monoclonal Antibody Product Candidates for Colorectal Cancer           
6.5.2    Trials Using Checkpoint Inhibitors and Immune Modulators for Colorectal Cancer       
6.5.3    Clinical Trials for Vaccines Indicated for Colorectal Cancer               
6.5.4    Adoptive Cell Therapy for Colorectal Cancer                       
6.5.5    Oncolytic Virus Therapy for Colorectal Cancer                       
6.5.6    Adjuvant Immunotherapy for Colorectal Cancer                       
6.5.7    Cytokines for Colorectal Cancer                               
6.6    Immunotherapies in Development for Lymphoma                   
6.6.1    Therapeutic Vaccines in Development for Lymphoma                   
6.6.2    Checkpoint Inhibitors for Lymphoma                           
6.6.3    Adoptive T Cell Transfer for Lymphoma                           
6.6.4    Monoclonal Antibodies for Lymphoma                           
6.7    Immunotherapy for Kidney Cancer                           
6.7.1    Checkpoint Inhibitors for Kidney Cancer                           
6.7.2    Vaccines for Kidney Cancer                               
6.7.3    Adoptive Cell Therapy for Kidney Cancer                           
6.8    Dominance of MAbs and Vaccines in Cancer Clinical Research               
6.9    Oncology Biologics Losing Patent Protection                       

7.0    Cancer Incidence and Mortality: An Overview                   
7.1    Global Economic Burden of Cancer                           
7.2    Global Burden of Cancer                                   
7.3    Top Five Most Frequent Cancers, Globally                       
7.3.1    Global Prevalence of Colorectal, Breast and Lung Cancers               
7.3.2    Percentage of Top Three Cancers Diagnosed Globally                   
7.3.2.1    Mortality due to Lung, Liver and Stomach Cancers                   
7.3.2.2    Percentage of Death due to Lung, Liver and Stomach Cancers               
7.4    Cancer Deaths in Women                               
7.5    Prevalence and Mortality for Cancer Types Addressed by Immunotherapy           
7.5.1    Breast Cancer                                       
7.5.1.1    Worldwide Incidence of Breast Cancer and Mortality Rate by Geography           
7.5.1.2    Female Breast Cancer Incidence in the U.S                       
7.5.1.3    Five Year Breast Cancer Survival Rates by Stage at Diagnosis and Age in the U.S       
7.5.1.4    Breast Cancer Incidence in Canada                           
7.5.1.5    Breast Cancer Incidence and Mortality in Latin America                   
7.5.1.6    Breast Cancer Incidence and Mortality in Europe                       
7.5.1.7    Breast Cancer Incidence in Asia/Pacific                           
7.5.1.8    Breast Cancer Incidence by Country                           
7.5.2    Gastric Cancer (Stomach Cancer)                           
7.5.2.1    Incidence of Gastric Cancer in Top 15 Countries                       
7.5.3    Colorectal Cancer                                   
7.5.3.1    Global Incidence of Colorectal Cancer                           
7.5.3.2    Worldwide Variations in the Incidence of Colorectal Cancer               
7.5.3.3    Risk Factors for Colorectal Cancer                           
7.5.3.4    Colorectal Cancer Screening in the U.S                           
7.5.3.5    Colorectal Cancer Incidence Rates in the U.S. by State                   
7.5.3.6    Colorectal Cancer Mortality Rates (per 100,000) in the U.S. by States           
7.5.4    Lung Cancer                                       
7.5.4.1    Non-Small Cell Lung Cancer (NSCLC)                           
7.5.4.2    Global NSCLC Incidence                                   
7.5.4.3    Lung Cancer in Americas by Gender                       
7.5.4.4    Tobacco Use and Lung Cancer                               
7.5.4.5    Current Therapeutic Options for Lung Cancer                       
7.5.5    Glioblastoma                                       
7.5.5.1    Global Incidence of Glioblastoma                           
7.5.6    Kidney Cancer                                       
7.5.6.1    Global Incidence of Kidney Cancer                           
7.5.7    Blood Cancer                                       
7.5.7.1    Leukemia                                   
7.5.7.2    Blood Cancer in the U.S                                   
7.5.8    Cervical Cancer                                       
7.5.8.1    Global Incidence of Cervical Cancer                           
7.5.9    Prostate Cancer                                       
7.5.9.1    Global Incidence of Prostate Cancer                           
7.5.9.2    Prostate Cancer Incidence and Mortality by Geography                   
7.5.9.3    Prostrate Cancer in the U. S                               
7.5.10    Melanoma                                       
7.5.10.1 Skin Cancer in the U. S                                   

8.0    Market Analysis                                   
8.1    Global Oncology Market                                   
8.2    Top Ten Companies in Oncology Drug Sales                       
8.3    Top Five Oncology Drugs                               
8.4    Global Oncology Therapeutics Market by Cancer Type                   

9.0    Market for Cancer Immunotherapy                           
9.1    Key Drivers                                       
9.2    Global Market for Cancer Immunotherapeutics                       
9.3    Global Market for Cancer Immunotherapy by Product Class               
9.4    Global Market for Immunotherapy Drugs by Cancer Type                   
9.5    Global Market for Monoclonal Antibodies for Cancer by Type               
9.5.1    Best Selling MAbs                                   
9.5.1.1    Market Forecast for Herceptin                               
9.5.1.2    Market Value and Forecast for Avastin                           
9.5.1.3    Global Market for Erbitux                               
9.5.1.4    Global Market for Yervoy                               
9.5.1.5    Global Market for Mabthera                               
9.5.2    Global Market for Antibody Drug Conjugates (ADCs)                   
9.5.2.1    Global Market for Adcetris                               
9.5.2.2    Global Market for Keytruda                               
9.6    Global Market for Cancer Vaccines                           
9.6.1    Global Market for Cancer Vaccines by Type                       
9.7    Global Market for Non-Specific Cancer Immunotherapeutics               
9.8    Market Values for Selected Forthcoming Cancer Immunotherapeutics           
9.8.1    Market Value for Nivolumab (Opdivo)                           
9.8.2    Market Value for Tecentriq                               
9.8.3    Market Value for DCVax-L                               
9.8.4    Market Value for Imfinzi                               
9.8.5    High Cost of MAbs                                   

10.0    Company Profiles                                   
10.1    Ablynx NV                                       
10.2    Activartis Biotech GmbH                                   
10.2.1    GBM Vax Study                                       
10.3    Advaxis Inc                                       
10.3.1    Advaxis’ Technology                                   
10.3.2    Advaxis’ Product Pipeline                               
10.3.2.1     ADXS-HPV                                   
10.3.2.2     ADXS-PSA                                   
10.3.2.3     ADXS-cHER2                                   
10.4    Aduro BioTech Inc                                   
10.4.1    Aduro’s Technology                                   
10.4.1.1        CRS-207                               
10.4.1.2        AUD-623                               
10.4.1.3        ADU-741                               
10.4.1.4        ADU-S100                               
10.5    Agenus Inc                                       
10.5.1    QS-21 Stimulon                                       
10.6    AlphaVax Inc                                       
10.6.1    Alpha Vax’s Technology                                   
10.7    A. Menarini Industrie Farmaceutiche Riunite Srl                       
10.7.1    MEN1112                                       
10.8    Amgen Inc                                       
10.8.1    Vectibix (panitumumab)                                   
10.8.2    Blinatumomab (Blincyto)                               
10.8.3    Rilotumumab                                       
10.9    Antigen Express Inc                                   
10.9.1    Li-Key Hybrid Vaccines (AE37)                               
10.10    Argos Therapeutics Inc                                   
10.10.1    AGS-003                                       
10.11    Bavarian Nordic A/S                                   
10.11.1    Prostvac                                       
10.11.2    CV-301                                               
10.11.3    MVA-BN PRP                                       
10.11.4    MVA-BN HER2                                       
10.11.4.1 MVA-BN Brachyury                                   
10.12    Bellicum Pharmaceuticals Inc                               
10.12.1    BPX-501                                       
10.12.2    BPX-201                                       
10.12.3    BPX-401                                       
10.12.4    BPX-601                                       
10.12.5    BPX-701                                       
10.13    Biogen Idec Inc                                       
10.13.1    Rituxan (Rituximab)                                   
10.13.2    Gazyva (Obinutuzumab)                                   
10.14    Biovest International Inc                               
10.14.1    BiovaxID                                       
10.15    Bristol-Myers Squibb Company                               
10.15.1    Erbitux (cetuximab)                                   
10.15.2    OPDIVO (nivolumab)                                   
10.15.3    Yervoy (ipilimumab)                                   
10.16    Cellectis                                           
10.17    Cellerant Therapeutics Inc                               
10.17.1    CLT-008                                       
10.17.2    CLT-009                                       
10.18    Celldex Therapeutics                                   
10.18.1    Rindopepimut                                       
10.18.2    Glembatumumab vedotin (CDX-011)                           
10.18.3    Varlilumab (CDX-1127)                                   
10.18.4    CDX-1401                                       
10.18.5    CDX-301                                       
10.19    CEL-SCI Corp.                                       
10.19.1    Multikine                                       
10.20    CureTech Ltd.                                       
10.20.1    Pidilizumab (CT-011)                                   
10.21    Delta-Vir GmbH                                       
10.21.1    Treatment                                       
10.22    Dendreon Corp.                                       
10.22.1    Provenge (Sipuleucel-T)                                   
10.23    DenDrit Biotech USA                                   
10.23.1    MelCancerVac                                       
10.24    DNAtrix Inc                                       
10.24.1    DNX-2401                                       
10.25    Eli Lilly and Co.                                       
10.25.1    Erbitux (Cetuximab)                                   
10.26    EMD Serono Inc                                       
10.27    Etubics Corp.                                       
10.28    Galena Biopharma Inc                                   
10.29    Genentech Inc                                       
10.29.1    Avastin (bevacizumab) for Metastatic Colorectal Cancer                   
10.29.1.1    Avastin and Interferon Alfa for Metastatic Kidney Cancer               
10.29.1.2    Avastin for Metastatic NLCLC                           
10.29.2    Gazyva (obinutuzumab) for Chronic Lymphocytic Leukemia               
10.29.3    Herceptin (trastuzumab) for Breast Cancer                       
10.29.3.1    Herceptin and Chemotherapy for Gastric Cancer                   
10.29.4    Kadcyla (ado-trastuzumab emtansine)                           
10.29.5    Perjeta (pertuzumab)                                   
10.29.6    Rituxan (rituximab)                                   
10.29.7    Genentech’s Cancer Immunotherapy Pipeline Products                   
10.30    Genmab AS                                       
10.30.1    Ofatumumab                                       
10.31    GlaxoSmithKline                                       
10.31.1    Arzerra (Ofatumumab)                                   
10.31.2    Cervarix                                           
10.32    Gliknik Inc                                       
10.33    GlobeImmune Inc                                   
10.34    Heat Biologics Inc                                   
10.35    Immatics Biotechnologies GmbH                               
10.36    ImmunoCellular Therapeutics Ltd.                           
10.37    Immunocore Ltd.                                   
10.37.1    Product Pipeline                                       
10.38    ImmunoFrontier Inc                                   
10.39    ImmunoGen Inc                                       
10.39.1    IMGN853                                       
10.39.2    IMGN529                                       
10.39.3    IMGN289                                       
10.39.4    IMGN779                                       
10.40    Immunomedics Inc                                   
10.41    Immunotope Inc                                   
10.41.1    IMT-1012 Immunotherapeutic Vaccine                           
10.42    Immunovaccine Inc                                   
10.43    Inovio Pharmaceuticals Inc                               
10.44    Janssen Biotech Inc                                   
10.44.1    Doxil                                           
10.44.2    Procrit                                           
10.44.3    Zytiga                                           
10.44.4    Imbruvicia                                       
10.45    Juno Therapeutics Inc                                   
10.46    Kite Pharma Inc                                       
10.46.1    Kite Pharma’s Technology                               
10.46.1.1    eACT (engineered Autologous Cell Therapy)                   
10.46.1.2    DC-Ad GM-CAIX                                   
10.47    MabVax Therapeutics Holdings Inc                           
10.48    MedImmune LLC                                   
10.49    Merck & Co., Inc                                   
10.49.1    Gardasil (Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine       
10.49.2    Keytruda (Pembrolizumab)                               
10.50    Merrimack Pharmaceuticals Inc                               
10.51    Morphotek Inc                                       
10.51.1    Farletuzumab (MORAb-003)                               
10.51.2    Amatuximab (MORAb-009)                               
10.51.3    Ontuxizumab (MORAb-004)                               
10.51.4    MORAb-066                                       
10.52    NewLink Genetics Corp.                                   
10.53    Northwest Biotherapeutics Inc                               
10.54    NovaRx Corp.                                       
10.55    OncoPep Inc                                       
10.55.1    PVX-410                                       
10.56    Oncothyreon Inc                                   
10.57    OSE Pharma SA                                       
10.58    Oxford BioTherapeutics Ltd.                               
10.58.1    Technologies                                       
10.58.1.1 OGAP – Cancer Targeting                               
10.58.1.2 Antibody Development                               
10.58.1.3 Antibody “arming”                                   
10.58.2     Lead Programs                                       
10.58.2.1  OX001/MEN1112                                   
10.58.2.2  OX002                                       
10.58.2.3  OX003                                       
10.58.2.4  OX004                                       
10.59    Pique Therapeutics                                   
10.60    Polynoma LLC                                       
10.60.1    MAVIS Trial                                       
10.61    Prima BioMed Ltd.                                   
10.62    Progenics Pharmaceuticals Inc                               
10.62.1    PSMA Targeted Imaging Compound (1404)                       
10.62.2    PSMA ADC Therapeutic                                   
10.62.3    Small Molecule Therapeutic (1095)                           
10.62.4    Azedra                                           
10.63    Regen Biopharma Inc                                   
10.63.1    HemaXellerate                                       
10.63.2    dCellVax                                       
10.63.3    Diffron C                                       
10.64    Roche Holdings Inc                                   
10.64.1    Avastin (Bevacizumab)                                   
10.64.2    Gazyva/Gazyvaro (Obinutuzumab; GA101)                       
10.64.3    Herceptin (Trastuzumab)                               
10.64.4    Kadcyla (Trastuzumabum emtansinum)                           
10.64.5    Mabthera (Rituximab)                                   
10.64.6    Perjeta (Pertuzumab)                                   
10.65    Seattle Genetics Inc                                   
10.65.1    Adcetris (Brentuximab vedotin)                               
10.65.2    Seattle Genetics’ Collaborarator Pipeline                           
10.66    Sorrento Therapeutics Inc                               
10.66.1    Sorrento’s Antibody Technologies                           
10.66.1.1  G-MAB                                       
10.66.1.2  Antibody Drug Conjugates (ADCs)                           
10.67    Spectrum Pharmaceuticals Inc                               
10.67.1    Zevalin                                           
10.68    Synthon Pharmaceuticals Inc                               
10.69    TapImmune Inc                                       
10.70    ThioLogics Ltd.                                       
10.71    Transgene SA                                       
10.72    TVAX Biomedical Inc                                   
10.72.1    TVI-Brain-1                                       
10.72.2    TVI-Kidney-1                                       
10.73    Vaccinogen Inc                                       
10.74    Viventia Biotechnologies Inc                               
10.75    Wilex AG                                       
10.76    Ziopharm Oncology Inc                                   

11.0   Cancer Immunotherapy Market Participants by Product Segment   

12.0    CAR T Therapy                                   
12.1    Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy        
12.1.1    Clinical Status of CD19 CAR-T Cells To Date                        
12.1.2    Clinical and Regulatory Challenges for Development of CAR T Cells              
12.1.3    Key Regulatory Challenges Associated with CAR-T Development                
12.1.4    Summary of Select CAR-T Products by Juno, Novartis and Kite                 
12.1.5    Clinical Benefit Versus Toxicity in CD19-Directed ALL Clinical Trials            
12.1.6    How to Manage Toxicity of CAR-T Therapy                        

13.0    Regulations Pertaining to Immunotherapy Regulation in the USA            
13.1    Center for Biologics Evaluation and Research (CBER)                    
13.1.1    Compliance and Surveillance                                
13.1.2    Extra Resources on Immunotherapeutics from the FDA                    
13.1.3    Cellular, Tissue and Gene Therapies Advisory Committee                
13.1.4    Consumer Affairs Branch (CBER) Contact in FDA                        
13.1.5    FDA Regulations Pertaining to Immunotherapies                        
13.1.6    Case Study Ovarian Cancer Immunotherapy Regulations                    
13.1.6.1        Efficacy                                
13.1.6.2        Adverse Effects                                
13.1.7    Trial Design Considerations for Immunotherapy                        
13.1.8    Development of Immune-Related Response Criteria (irRC) & Clinical Endpoints Specific to Immunotherapies                                        

14.0    Regulations for Immunotherapy in Japan                        
14.1    PMDA and Immunotherapy                               
14.1.1    Increasing the Efficiency in Immunotherapy Regulatory Review                
14.1.2    Forerunner Review Assignment System                            
14.1.3    Revised Guidelines for Clinical Evaluation of Anti-Malignant Tumor Agents        
14.1.4    Key Contacts Within the PMDA for Immunotherapeutics                    

15.0    European Regulation and Immunotherapeutics                    
15.1    Introduction                                        
15.2    Challenges for Immunotherapy in EMEA                            
15.2.1    EMA Status on Potency Testing                                
15.2.1.1        In Vivo Potency Testing                            
15.2.1.2        In Vitro Potency Testing                        
15.2.1.3        Viable Cell Count                            
15.2.1.4        Autologous Cell Based Products                        
15.2.1.5        Reference Preparation                            
15.2.1.6        Adjuvant Containing Immunotherapy Products               
15.2.2    EMA Status on Identifying hyper, Hypo or non-Responders                
15.3    Challenges Relating to Biomarkers in Immunotherapy                    
15.4    Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy        
15.5    Estimating Optimal Cut-Off Parameters                            
15.6    EU-Approved Immunotherapies in Melanoma                        
15.7    Key Contacts Within EMA for Immunotherapeutics                    

16.0    Manufacturing of Immunotherapies                        
16.1    Introduction                                        
16.2    Generation of CAR-Modified T Cells                            
16.2.1    What Co-Stimulation and Activity Domain is Optimal to Use?                
16.2.2    Optimizing Cell Culture Media                                
16.2.3    Manufacturing Lentiviral Vectors                            
16.2.4    Detection of Integrated CAR-Expressing Vectors                        
16.2.5    Donor Lymphocyte Infusion Procedure                            
16.2.6    Ex Vivo Costimulation & Expansion of Donor T Cells                    
16.2.7    Infusion to the Patient                                    
16.3    Manufacturing Devices and Instruments Required for Immunotherapy Production       
16.3.1    Leukapheresis                                        
16.3.2    Cell Counters and Analyzer                                
16.3.3    Cell Seeding, Growth and Propagation                            
16.4    Good Manufacturing Procedure (GMP) for Immunotherapy                
16.5    Case Study Production of Lentivirus Induced Dendritic Cells under GMP Conditions    
16.6    Quality Control                                        
16.7    Regulatory Affairs                                    
16.8    Key Challenges in Manufacturing                            
16.8.1    Electroporation of T-cells                                
16.8.2    Allogenic CAR T cells                                    
16.8.3    Relapse Rates are Critical                                
16.8.4    Antigen Negative Relapse                                
16.8.5    Incorporating Suicide Genes                                
16.8.16    Automation in Cell Therapy Manufacturing                        
16.8.17    Autologous Cell Therapy Manufacture Scale Up                        

17.0    Supply Chain & Logistics                                
17.1    Introduction                                        
17.2    Case Study: Juno Therapeutics                                

18.0    Pricing & Cost Analysis                                
18.1    Introduction                                        
18.2    CAR T Therapy Market Evaluation                            

19.0    Current Deals Within the CAR T Market                        

20.0    CAR T Therapy Company Case Studies                       
20.1    Juno Therapeutics                                   
20.2    Kite Pharma                                       
20.3    Cellectis                                           

Appendix
A1    Highlights and Approvals in 2017
A2    Highlights and Approvals in 2016

INDEX OF FIGURES
Figure 2.1: Components of an Antibody Drug Conjugate (ADC)                   
Figure 2.2: Mechanism of Action of Antibody Drug Conjugates                   
Figure 2.3: Ranking of Commonly Used Cytotoxin Wareheads                   
Figure 4.1: Number of Successful and Unsuccessful Melanoma  Drugs               
Figure 4.2: Successes and Failures in Lung Cancer Medicine Development           
Figure 4.3: Successes and Failures in Brain Cancer Drug Development               
Figure 5.1: Ibritumomab Linked to Yttrium Radfionucleotide                   
Figure 5.2: Kadcyla (Trastuzumab + DMI)                           
Figure 6.1: Dominance of MAbs and Vaccines in Cancer Clinical Research               
Figure 7.1: Global Economic Burden of Cancer                           
Figure 7.2: Number of Colorectal, Breast and Lung Cancer Cases Diagnosed Globally       
Figure 7.3 Percentage of Top Three Cancers Diagnosed Globally                   
Figure 7.4: Number of Deaths due to Lung, Liver and Stomach Cancers Globally           
Figure 7.5: Percentage of Deaths due to Lung, Liver and Stomach Cancers           
Figure 7.6: Global Cancer Deaths in Women by Type of Cancer                   
Figure 7.7: Worldwide Incidence of Female Breast Cancer and Mortality Rate by Geography   
Figure 7.8: Five Year Relative US Breast Cancer Survival Rates by Stage at Diagnosis & Age   
Figure 7.9: Breast Cancer Incidence and Mortality in Latin America               
Figure 7.10: Breast Cancer Incidence and Mortality in Europe                   
Figure 7.11: Breast Cancer Incidence Rates in Asia/Pacific Region               
Figure 7.12: Top 15 Countries in Gastric Cancer Incidence                   
Figure 7.13: Top 15 Countries in Colorectal Cancer Incidence                   
Figure 7.14: Adults Aged 50-75 Years (%) That are Up-to-Date with Colorectal Screening Tests by State in the U.S                                                 
Figure 7.15 Colorectal Cancer Incidence Rates (per 100,000) by State in the U.S           
Figure 7.16: Colorectal Cancer Mortality Rates (per 100,000) in the U.S. by States       
Figure 7.17: Top 15 Countries with Lung Cancer                           
Figure 7.18: Global NSCLC Incidence                               
Figure 7.19: Number of Smokers in China, India, Russia, the U.K. and U.S           
Figure 7.20: Global Incidence of Glioblastoma                           
Figure 7.21: Global Incidence of Kidney Cancer                           
Figure 7.22: Top 15 Countries in Leukemia Mortality                       
Figure 7.23: Five Year Survival Rates in the U.S. for Blood Cancer Patients           
Figure 7.24 Top 15 Countries in Cervical Cancer                           
Figure 7.25: Top 15 Countries with Prostate Cancer                       
Figure 7.26: Skin Cancer Death Rates for Top 15 Countries                   
Figure 8.1: Global Market for Oncology Drugs by Geography/Country, Through 2022       
Figure 8.2: Global Oncology Drug Sales by Top Five Companies, Through 2022           
Figure 8.3: Top Five Oncology Drugs, Through 2022                       
Figure 8.4: Global Oncology Therapeutics Market by Cancer Type                   
Figure 9.1: Global Cancer Immunotherapy Market, Through 2022                   
Figure 9.2: Global Market for Immunotherapy by Product Class, Through 2022           
Figure 9.3: Global Market for Immunotherapy Drugs by Cancer Type, Through 2022         
Figure 9.4: Global Market for Monoclonal Antibodies for Cancer by Type, Through 2022       
Figure 9.5: Global and U.S. Market for Herceptin, Through 2022                   
Figure 9.6: Global and U.S. Market for Avastin, Through 2022                   
Figure 9.7: Global Market for Erbitux, Through 2022                       
Figure 9.8: Global Market for Yervoy, Through 2022                       
Figure 9.9: Global Market for Mabthera, Through 2022                       
Figure 9.10: Global Market for Adcetris, Through 2022                       
Figure 9.11: Global Market for Keytruda, Through 2022                       
Figure 9.12: Global Market for Cancer Vaccines, Through 2022                   
Figure 9.13: Global Market for Cancer Vaccines by Type, Through 2022               
Figure 9.14: Global Market for Cytokine Drugs for Cancer, Through 2022               
Figure 13.1: Clinical Regulatory Pathway – Conventional Route                    
Figure 13.2: Clinical Regulatory Pathway – Option for Rapid Translation                
Figure 14.1: PMDA Total Review Period of Standard Drugs                    
Figure 14.2: PMDA Total Review Period of Priority Drugs                        
Figure 14.3: Number of Approved Recombinant Protein Products by PMDA           
Figure 14.4: Forerunner Review Assignment System Timeframe                    
Figure 14.5: Adaptive Licensing and Accelerated Approval in Japan-US-EU            
Figure 15.1: CheckMate 066 Clinical Trial                            
Figure 15.2: CheckMate 037 Clinical Trial                            
Figure 16.1: Method of Generating CAR-Modified T Cells                        
Figure 16.2: Clinical Activity, Cost Structure Patient Flow Chart of CAR-T Therapy        
Figure 16.3: Allogenic Versus Autologous Cell Manufacturing                    
Figure 17.1: Streptamer® -Based Magnetic Bead Cell Isolation                    
Figure 18.1: Annual Cost of Patented Cancer Therapeutics from 2000 to Today            
Figure 18.2: Cost of Nivolumab, Pembrolizumab & Ipilimumab per mg                 
Figure 20.1 Juno Therapeutics CAR T Therapeutic Molecular Design               
Figure 20.2 Juno Therapeutics CAR T Therapeutic Mechanism of Action               
Figure 20.3 Juno Therapeutics T Cell Receptor (TCR) Technology Mechanism of Action       
Figure 20.4: Streptamer® -Based Magnetic Bead Cell Isolation                   
Figure 20.5 Kite Pharma CAR Technology                           
Figure 20.6 Kite Pharma TCR Technology                           

INDEX OF TABLES
Table 2.1: Types of Immune Cells and their Functions                           
Table 2.2: FDA-Approved Cancer Immunotherapies                           
Table 2.3: FDA-Approved Monoclonal Antibodies (MAbs) to Treat Cancer                   
Table 2.4: Most Frequently Targeted Antigens by MAbs                           
Table 2.5: FDA-Approved Monoclonal Antibodies                               
Table 2.6: Cytotoxic Wareheads Used in ADCs                               
Table 2.7: Targeted Indications for ADCs                               
Table 2.8: Antibody Drug Conjugates: Developmental Tmeline                       
Table 2.9: Target Antigens for ADCs in Preclinical and Clinical Development               
Table 2.10: Current ADCs Launched, Withdrawn and in Phase I/II/III Trials by Sponsor, Indication, Antigen, Cytotoxin and Linker                                             
Table 2.11: MAb Products and Candidates that Recruit T Cells                       
Table 2.12: Bispecific MAbs in Clinical Trials Targeting Cancer by Indication and Company           
Table 2.13: Bispecific Antibody Technology Platforms                           
Table 2.14: Side Effects of Some of the Approved Cancer Immunotherapy MAbs               
Table 2.15: FDA-Approved Cancer Vaccines                               
Table 2.16: Cancer Vaccines in Development                               
Table 2.17: FDA-Approved Cytokines for Cancer Immunotherapy                   
Table 2.18: Cancer Indications Approved for IFN-alfa                           
Table 2.19: FDA-Approved Immune Checkpoint Modulators                       
Table 2.20: Immune Checkpoint Inhibitors in Clinical Development                   
Table 2.21: Cancer Immunotherapy: Timeline of Progress                       
Table 3.1: PD-1 Therapies Targeting either the PD-L1/L2 or PD-1 Receptor               
Table 3.2: Overview of Clinical Trial Landscape for Top Five Anti-PD-1 and Anti-PD-L1 Drugs       
Table 3.3: Nivolumab Efficacy from Expansion Cohorts of Study 003                   
Table 3.4: Phase I Data of Keytruda in Melanoma                           
Table 3.5: Phase I Data of Tecentriq in NSCLC Patients                           
Table 3.6: Tecentriq Phase I Data from RCC Patients                           
Table 3.7: Phase I Melanoma Data for Tecentriq                               
Table 3.8: Phase II Data for Pidilizumab in Diffuse Large B Cell Lymphoma (DLBCL)           
Table 3.9: Phase II Melanoma Data for Pidilizumab                           
Table 3.10: An Overview of Anti-PD-1 Development by Company, Drug Candidate, Indication and Clinical Phase                                                     
Table 3.11: Clinical Development of CTLA-4, TIM3, and LAG3 Checkpoint Inhibitors by Company, Drug Candidate, Indication and Clinical Trial Stage                                 
Table 3.12: Pivotal Phase III Results for Yervoy in Second-Line Patients with Metastatic Melanoma   
Table 3.13: Updated Data from Phase III Clinical Study 024 for Yervoy                   
Table 3.14: Data from the Failed Phase III Study of Tremelimumab for Melanoma           
Table 3.15: An Overview of Clinical Development of Dendritic Cell Therapies by Company, Drug Candidate, Indication and Clinical Phase                                         
Table 3.16: Pivotal Phase III Rwesults for Yervoy in Second-Line Patients with Metastatic Melanoma..     
Table 3.17: Phase I/Iia Results from Kite Pharma’s CAR-T Therapy                     
Table 3.18: Cancer Vaccines in Development by Company, Drug Candidate, Indication & Clinical Phase     
Table 3.19: Advaxis Phase II Results for Cervical Cancer Patients in India                   
Table 3.20: Phase II Data for Contego                                   
Table 3.21: Valuable R&D Projects in Cancer Immunotherapy                       
Table 6.1: Cancer Types Addressed by Immunotherapies by Drug, Trade Name and Company       
Table 6.2: Oncology Drugs Losing Patent Protection by 2020 by Product, U.S. Expiry Date and E.U. Expiry Date                                                
Table 7.1: Global Cancer Statistics – Key Facts                           
Table 7.2: Top Five Most Frequent Cancers, Globally                       
Table 7.3: Estimated Breast Cancer Cases and Deaths in the U.S. by Age               
Table 7.4: Estimated Canadian Breast Cancer Statistics                       
Table 7.5: Age-Standardized Breast Cancer Incidence Rate per 100,000 Women by Country
Table 7.6: Global Colorectal Cancer Incidence and Mortality Rates by Gender per 100,000 people   
Table 7.7: Risk Factors for Colorectal Cancer                           
Table 7.8: Lung Cancer Incidence and Mortality Rate in Americas by Gender           
Table 7.9: Current Therapeutic Options for Lung Cancer                       
Table 7.10: Estimated Number of New Leukemia Cases in the U.S.               
Table 7.11: Estimated Deaths in the U.S. from Leukemia                       
Table 7.12: Estimated Deaths from HL and NHL in the U.S.                   
Table 7.13: Estimated Incidence and Deaths for Myeloma in the U.S.               
Table 7.14 Global Prostate Cancer Incidence and Mortality Rates by Geography           
Table 7.15: Incidence and Mortality Rates of Prostate Cancer in Americas               
Table 7.16: Incidence and Mortality Rates for Melanoma in Americas               
Table 8.1: Global Market for Oncology Drugs by Geography/Country, Through 2022       
Table 8.2: Top Ten Companies in Oncology Sales, Through 2022                   
Table 8.3: Top Five Oncology Drugs, Through 2022                           
Table 9.1: Global Cancer Immunotherapy Market, Through 2022                   
Table 9.2: Global Market for Immunotherapy by Product Class, Through 2022           
Table 9.3: Global Market for Immunotherapy Drugs by Cancer Type, Through 2022       
Table 9.4: Global Market for Monoclonal Antibodies for Cancer by Type, Through 2022       
Table 9.5: Global and U.S. Market for Herceptin, Through 2022                   
Table 9.6: Global and U.S. Market for Avastin, Through 2022                   
Table 9.7: Global Market for Cancer Vaccines, Through 2022                   
Table 9.8: Global Market for Cancer Vaccines by Type, Through 2022               
Table 9.9: Projected Market for the Forthcoming DCVax-L and Imfinzi
Table 9.10: Annual Cost of MAbs in the U.S. by Product, Indication and Biomarker       
Table 10.1: Ablynx’s Product Pipeline                               
Table 10.2: Aduro’s Product Pipeline                               
Table 10.3: Agenus’ Product Pipeline                               
Table 10.4: AlphaVax Cancer Immunology Product Pipeline                   
Table 10.5: Amgen’s Product Pipeline                               
Table 10.6: Antigen Express’ Cancer Therapeutic Pipeline                       
Table 10.7: Argos’ Cancer Product Pipeline                           
Table 10.8: Bavarian Nordic’s Product Pipenine                           
Table 10.9: Bellicum’s Pipeline Product Candidatea                       
Table 10.10: Biogen’s Oncology Pipeline                               
Table 10.11: Bristol-Myers Squibb’s Pipeline Products in Cancer Immunotherapy           
Table 10.12: Cellectis’ Products in Development                           
Table 10.13: Cellerant’s Product Pipeline                               
Table 10.14: Celldex’s Therapeutic Pipeline                           
Table 10.15: CEL-SCI’s Immunotherapy Products in Development               
Table 10.16: EMD Serono’s Product Pipeline                           
Table 10.17: Etubic’s Product Pipeline                               
Table 10.18: Galena’s Product Pipeline                               
Table 10.19: Genentech’s Cancer Immunotherapy Pipeline Products               
Table 10.20: Genmab’s Products in Development                           
Table 10.21: Gliknik’s Product Pipeline                               
Table 10.22: GlobeImmune’s Product Pipeline                           
Table 10.23: Heat Biologic’s Product Pipeline                           
Table 10.24: Immatics Biotechnology’s Product Pipeline                       
Table 10.25: ImmunoCellular’s Product Pipeline                           
Table 10.26: Immunomedics’ Late-Stage Antibody-Based Therapies               
Table 10.27: Immunovaccine’s Product Pipeline                           
Table 10.28: Inovio Pharmaceuticals Product Pipeline                       
Table 10.29: Juno Therapeutics’ Current Pipeline                           
Table 10.30: Kite Pharma’s Product Pipeline                           
Table 10.31: MabVax’s Product Pipeline                               
Table 10.32: MedImmune’s Products in Development                       
Table 10.33: Merck’s Pipeline of Cancer Immunotherapy Products               
Table 10.34: Merrimack’s Product Pipeline                           
Table 10.35: NewLink Genetics’ Product Pipeline                           
Table 10.36: Northwest’s Product Pipeline                           
Table 10.37: NovaRx Clinical Development Pipeline                       
Table 10.38: Oncothyreon’s Immunotherapy Product Pipeline                   
Table 10.39: OSE Pharma’s Product Pipeline                           
Table 10.40: Pique Therapeutics’ Product Pipeline                       
Table 10.41: Prima BioMed’s Pipeline                               
Table 10.42: Progenics Pharmaceutical’s Pipeline                           
Table 10.43: Roche Holding’s Cancer Immunotherapy Product Pipeline               
Table 10.44: Seattle Genetics’ Pipeline Products                           
Table 10.45: Seattle Genetics’ Collaborarator Pipeline                       
Table 10.46: Synthon Biopharmaceuticals’ Pipeline                       
Table 10.47: TapImmune’s Product Pipeline                           
Table 10.48: ThioLogic’s Product Pipeline                           
Table 10.49: Transgene’s Product Pipeline                           
Table 10.50: Vaccinogen’s Product Pipeline                           
Table 10.51: Viventia’s Product Pipeline                               
Table 10.52: Wilex’s Product Pipeline                               
Table 10.53: Ziopharm’s Products in Development                       
Table 11.1: Cancer Immunotherapy Market Participants by Product Segment           
Table 12.1: Selected CD19-directed Product Candidates in Clinical Trials by Costimulatory & Binding Domains, Starting Cell Population, Vector and Ablation Technology                    
Table 12.2: Select CD19-Directed ALL Clinical Trials                        
Table 12.3: Select Anti-CD22 CAR-T Clinical Projects                        
Table 13.1: CBER Compliance and Surveillance Activities                        
Table 13.2: Contacts for the Cellular, Tissue and Gene Therapies Advisory Committee, FDA    
Table 14.1: Key Contacts Within PMDA, Japan                            
Table 15.1: Contact Details for EMA Immunotherapy Experts                    
Table 16.1: General Technical and Personnel Requirements of a GMP, QC, QA, FDA Regulated Cell Therapy Manufacturing Facility                                        
Table 16.2: Technician/Scientific Requirements for CAR T Manufacturing                
Table 16.3: Selection of Apheresis Instruments Currently on the Market                
Table 16.4: Selection of Cell Counters and Analyzer Instruments Currently on the Market        
Table 16.5: Main Objectives of GMP Manufacturing Immunotherapeutics                
Table 16.6: Main Objectives of Quality Control While Manufacturing Immunotherapeutics        
Table 16.7: Main Objectives of Regulatory Affairs During Manufacturing Immunotherapeutics    
Table 16.8: CAR-T Studies Using mRNA Transfection Electroporation                
Table 16.9: Challenges for Autologous Cell Therapy Manufacture                    
Table 16.10: Current Company/Institutions with Suicide Gene CAR T Projects            
Table 16.11: Advantages of Using Automated Cell Therapy Manufacturing            
Table 16.12: Main Drivers to Implement Automated Cell Therapy Manufacturing            
Table 16.13: Main Benefits of Automated Cell Therapy Manufacturing                
Table 16.14: Advantages & Disadvantages of Autologous Cell Therapy Manufacture Scale Up    
Table 17.1: Juno Therapeutics Manufacturing Facility Objectives                    
Table 18.1: Current Juno Therapeutics Trials and CAR T Products                
Table 19.1: Current CAR T Business Deals                           
Table 20.1: Juno Therapeutics Target Biomarker Portfolio                   
Table 20.2 Juno Therapeutics CAR Technology                       
Table 20.3 Juno Therapeutics T Cell Receptor (TCR) Technology                       
Table 20.4 Juno Therapeutics Clinical Pipeline by Target, Product and Trial           
Table 20.5: Select CD19-Directed ALL Clinical Trials                       
Table 20.6: Select Anti-CD22 CAR-T Clinical Projects                       
Table 20.7 Juno Therapeutics Manufacturing Facility Objectives                   
Table 20.8 Current Kite Pharma CAR T Clinical Studies and Trials                   
Table 20.9 Current Kite Pharma TCR Clinical Studies and Trials

Note: Product cover images may vary from those shown
3 of 7

Loading
LOADING...

4 of 7

FEATURED COMPANIES

  • Ablynx NV
  • Biogen Idec Inc
  • Eli Lilly and Co.
  • Immunocore Ltd.
  • Merck & Co., Inc
  • Regen Biopharma Inc
  • MORE

This analysis of the "Global & USA Cancer Immunotherapy Market Analysis to 2020” reveals that the cancer immunotherapy space will be a significant revenue generator (excess of $80 billion) for the biopharmaceutical industry by 2020. The market has been supported by the approval of Bristol-Myers’ Yervoy drug for melanoma, BMS's Opdivo and Merck's Keytruda, . Over the next decade, immunotherapies will be the backbone of cancer treatments in 60% of cancer types. It is forecast that by 2020, Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the top five cancer drugs. A single drug, Bristol-Myers Squibb’s Yervoy, for example has earned revenues of about $960 million in 2013 and it is expected to have a market value of $1,775.2 million in 2020. Industry Experts have predicted that Keytruda and Opdivo will generate sales revenues of $2.9 billion and $4.3 billion respectively in 2019.

The CAR-T industry is addressing unmet needs in specific relapsed cancers, however does early clinical trial data support a blockbuster status for this upcoming therapy? Some patients do indeed show long term activity and high remission rates, but there is a large proportion of patients with toxicities such as cytokine release syndrome and neurotoxicity. The main players within the CAR-T market are Juno Therapeutics, Kite Pharma, Novartis and Cellectis. The market is moving ahead, backed by years of R&D, from both academia and industry, investors capitol and small clinical studies. From 2017, the researcher forecasts that CAR T therapy will become more streamlined, with faster manufacturing times as advances in technologies take hold and clinical trials provide more robust evidence that this immunotherapy is robust. These factors, plus strategies to reduce adverse reactions and toxicities and larger players like Novartis taking stage will push CAR T therapy ahead. However, recent deaths in the Juno ROCKET trial are creating questions amongst investors. How will the CAR T space influence the total immunotherapy industry going forward? This comprehensive report scrutinizes the total market and provides cutting-edge insights and analysis.

“An unmet need in the cancer therapy market has paved the way for immunotherapies and has increased patient survival rates significantly” indicates Dr Deirdre Kelly. “Today significant therapeutic interest into ADC’s, checkpoint inhibitors, cancer vaccines and anti-PD-1/PD-L1 agents are taking the market by storm, and we forecast vertical growth in this area within the next decade’. Therefore it is no wonder that most science journals have hailed cancer immunotherapy as a significant breakthrough treatment.

The interest on ADCs can be seen with the recent approvals of Adcetris (brentuximab vedotin) and Kadcyla (ado-trastuzumab emtansine).  Currently, More than 15 companies are developing 30 different ADCs targeting both hematologic malignancies and solid tumors. ADCs represent a novel class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. As the ADCs carry a chemotherapy drug, they are believed to be more efficient and effective in the treatment of a disease. Due to shrinking pipelines and increasing pressure from patent expirations, big pharmaco’ recognized the vaccine market as a potential resource for investors. Cancer vaccines have been found to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines. The global market for cancer vaccines was worth about $4.4 billion and it is likely to reach $8.4 billion in 2020.

Immunotherapy is a proven powerful tool, either as a monotherapy or as a combination therapy with chemotherapy or radiation. For patients with metastatic skin cancer or kidney cancer, immunotherapy has been found to be more effective than the conventional options, with the possibility of even a complete cure. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone. This report describes the evolution of such a huge market in 20 chapters supported by over 180 tables and figures, over 317 pages.

Note: Product cover images may vary from those shown
5 of 7
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Ablynx NV
  • Activartis Biotech GmbH
  • Aduro BioTech Inc
  • Advaxis Inc
  • Agenus Inc
  • AlphaVax Inc
  • Amgen Inc
  • Antigen Express Inc
  • Argos Therapeutics Inc
  • Bavarian Nordic A/S
  • Bellicum Pharmaceuticals Inc
  • Biogen Idec Inc
  • Biovest International Inc
  • Bristol-Myers Squibb Company
  • CEL-SCI Corp.
  • Celldex Therapeutics
  • Cellectis
  • Cellerant Therapeutics Inc
  • CureTech Ltd.
  • DNAtrix Inc
  • Delta-Vir GmbH
  • DenDrit Biotech USA
  • Dendreon Corp.
  • EMD Serono Inc
  • Eli Lilly and Co.
  • Etubics Corp.
  • Galena Biopharma Inc
  • Genentech Inc
  • Genmab AS
  • GlaxoSmithKline
  • Gliknik Inc
  • GlobeImmune Inc
  • Heat Biologics Inc
  • Immatics Biotechnologies GmbH
  • ImmunoCellular Therapeutics Ltd.
  • ImmunoFrontier Inc
  • ImmunoGen Inc
  • Immunocore Ltd.
  • Immunomedics Inc
  • Immunotope Inc
  • Immunovaccine Inc
  • Inovio Pharmaceuticals Inc
  • Janssen Biotech Inc
  • Juno Therapeutics Inc
  • Kite Pharma Inc
  • MabVax Therapeutics Holdings Inc
  • MedImmune LLC
  • Merck & Co., Inc
  • Merrimack Pharmaceuticals Inc
  • Morphotek Inc
  • NewLink Genetics Corp.
  • Northwest Biotherapeutics Inc
  • NovaRx Corp.
  • OSE Pharma SA
  • OncoPep Inc
  • Oncothyreon Inc
  • Oxford BioTherapeutics Ltd.
  • Pique Therapeutics
  • Polynoma LLC
  • Prima BioMed Ltd.
  • Progenics Pharmaceuticals Inc
  • Regen Biopharma Inc
  • Roche Holdings Inc
  • Seattle Genetics Inc
  • Sorrento Therapeutics Inc
  • Spectrum Pharmaceuticals Inc
  • Synthon Pharmaceuticals Inc
  • TVAX Biomedical Inc
  • TapImmune Inc
  • ThioLogics Ltd.
  • Transgene SA
  • Vaccinogen Inc
  • Viventia Biotechnologies Inc
  • Wilex AG
  • Ziopharm Oncology Inc
Note: Product cover images may vary from those shown
6 of 7
The methodology is available for download below.
7 of 7
Note: Product cover images may vary from those shown
Adroll
adroll